Last week, the Health Ministry revealed that Parliament had allocated 18.8 million kroner to the testing of a State Serum Institute coronavirus vaccine.
Now, another player in Denmark has emerged.
In collaboration with Bavarian Nordic, AdaptVac and others, the University of Copenhagen is behind another promising COVID-19 vaccine that is ready to be tested on humans.
The vaccine requires financial backing to continue, but if everything proceeds as planned, human testing will begin in January.
“The consortium is now well positioned to scale this process with AGC Biologics to the billion-dose level once additional funding is secured,” AdaptVac wrote in a press release.
READ ALSO: Danish coronavirus vaccine gets financial backing
On the hunt for funding
The vaccine consists of unique technology that the researchers have developed and patented themselves.
So far, the researchers have proven that the vaccine is safe and works well on mice and non-human primates.
The next step is to test the vaccine on a smaller group of people in Germany or the Netherlands.
If all goes well, the scope of human testing will be increased and it is this step that will require the aforementioned financial support.
To this end, Bavarian Nordic is on the hunt for around two billion kroner in investment from private and public funds.
The vaccine could potentially be completed and approved for the public by the end of 2021.
